SYN004 / Synermore 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SYN004 / Synermore
NCT04692181: SYN-004 Safety and Tolerability in Allo-HCT Subjects

Recruiting
1b/2a
36
US
SYN-004, Ribaxamase or Placebo
Theriva Biologics, Inc., Washington University School of Medicine
121121000119106, Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder)
12/24
12/25
NCT04363242: A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Active, not recruiting
1
22
US
SYN125, SYN004
Synermore Biologics Co., Ltd., Synermore Biologics USA Limited
Epithelial Carcinoma, Solid Tumor
07/23
09/23

Download Options